Sentence examples for lesion response from inspiring English sources

Primary end point was progression-free survival (PFS); secondary end points included overall survival (OS), best target lesion response, safety, and tolerability.

Our data suggest a prediction of mCRC lesion response may be made immediately after radioembolisation using 90Y PET-derived dosimetry.

Aside from the four dose metrics, absorbed dose CoV was the parameter found to have the strongest association with lesion response in the univariate analysis (p = 0.001).

Outcome measures and timing of assessments   Primary outcome measure of lesion response at 48 to 72 h (≥20% reduction in lesion size when measured compared to baseline).

Lesion response sometimes does not take the appearance of shrinking, but rather progressive fading of the marrow abnormalities and return to normal marrow signal intensity within the lesion (Fig 14) [42].

This fatty halo sign indicates lesion response and parallels the appearance of fat within 'response' or 'healing' non-neoplastic conditions, such as chronic benign vertebral fractures, spondylodiscitis or degenerative disc disease.

Equivalent target lesion responses occurred in patients above and below the median age (54 vs. 49 % BORR, P = 0.8) and for men and women (58 vs. 41%%, P = 0.2).

Therefore, in this second subgroup of lesions (response subgroup 2), despite undergoing a good vascular response (⩾50% reduction in nE), only disease stabilisation was achieved (<30% decrease in size, but <20% increase in size; Figure 2).

In patients with measurable peritoneal lesions, response will be graded according to the RECIST 1.1 criteria: (1) complete response (CR), (2) partial response (PR, at least 30%% decrease in the sum of diameters of target lesions), (3) stable disease (SD) and (4) progressive disease (PD, new lesions or at least 20%% increase in the sum of diameters of target lesions) [ 40].

In these lesions, the change in enhancement was also variable (a range of −37.1 to+57.8), but there was significant overlap with the change observed in response subgroup 3. Therefore, this is a subgroup of lesions (response subgroup 4) characterised by a poor vascular response (<50% reduction in nE) and disease progression (⩾20% increase in size; Figure 2).

For lesions that could be assessed clinically (symptomatic and or superficial lesions) responses were typically noted by 7 10 days after therapy.